RESUMO
BACKGROUND: This study aimed to explore the effects of recombinant human thrombopoietin (rhTPO) on platelet recovery in decitabine, cytarabine, aclarubicin, and G-CSF (DCAG)-treated patients with intermediate-high-risk myelodysplastic syndrome/hypo proliferative acute myeloid leukemia. METHODS: Recruited patients were at a ratio of 1:1 into 2 groups: the rhTPO group (DCAGâ +â rhTPO) and control group (DCAG). The primary endpoint was the time for platelets to recover toâ ≥â 20â ×â 109/L. The secondary endpoints were the time for platelets to recover toâ ≥â 30â ×â 109/L andâ ≥â 50â ×â 109/L, overall survival (OS), and progression-free survival (PFS). RESULTS: The time required for platelet recovery toâ ≥â 20â ×â 109/L, ≥30â ×â 109/L, andâ ≥â 50â ×â 109/L in the rhTPO group was significantly shorter (6.5â ±â 2.2 vs 8.4â ±â 3.1 days, 9.0â ±â 2.7 vs 12.2â ±â 3.9 days, 12.4â ±â 4.7 vs 15.5â ±â 9.3 days, respectively; all Pâ <â .05 vs controls). The amount of platelet transfusion in the rhTPO group was smaller (4.4â ±â 3.1 vs 6.1â ±â 4.0 U, Pâ =â .047 vs controls). The bleeding score was lower (Pâ =â .045 vs controls). The OS and PFS were significantly different (Pâ =â .009 and Pâ =â .004). The multivariable analysis showed that age, karyotype, and time for PLT recovery toâ ≥â 20â ×â 109/L were independently associated with OS. Adverse events were similar. CONCLUSIONS: This study suggests that rhTPO leads to a faster platelet recovery after DCAG treatment, reduces the risk of bleeding, reduces the number of platelet transfusions, and prolongs the OS and PFS.
Assuntos
Leucemia Mieloide Aguda , Síndromes Mielodisplásicas , Humanos , Trombopoetina/uso terapêutico , Plaquetas , Proteínas Recombinantes/uso terapêutico , Síndromes Mielodisplásicas/tratamento farmacológico , Leucemia Mieloide Aguda/tratamento farmacológicoRESUMO
Intracranial epidermoid cysts, also known as epidermal cysts, grow slowly and may be occult. When small, epidermoid cysts are usually clinically unremarkable or cause no definitive symptoms. At typical sites, they are easily found through magnetic resonance imaging, which aids evaluation before surgery. However, in rare cases, epidermoid cysts are situated in unusual locations or transformed to malignancy, and preoperative misdiagnosis is possible. Here, the case of a 58-year-old male patient who presented with weakness in the left lower limb and was diagnosed with a malignant epidermoid cyst in the right frontoparietal lobe, right lateral ventricle, is reported. Surgery was performed to remove the tumour followed by radiotherapy, and the patient was reported to be living independently after approximately 11 months of follow-up.
Assuntos
Carcinoma de Células Escamosas , Cisto Epidérmico , Masculino , Humanos , Pessoa de Meia-Idade , Cisto Epidérmico/diagnóstico por imagem , Cisto Epidérmico/cirurgia , Carcinoma de Células Escamosas/diagnóstico por imagem , Carcinoma de Células Escamosas/cirurgia , Imageamento por Ressonância Magnética , Erros de DiagnósticoRESUMO
Although Indoleamine 2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO), and aryl hydrocarbon receptor (AHR) are involved in cancer immune escape, their prognostic impact on diffuse large B-cell lymphoma (DLBCL) is unknown.To examine the prognostic impact of IDO, TDO, and AHR on patients with DLBCL.This was a retrospective study on treatment-naïve patients with newly diagnosed DLBCL at the Henan Province People's Hospital between 01/2012 and 06/2015. Patients with inflammatory reactive lymph nodes were included as controls. All cases were reviewed by 2 pathologists. IDO, TDO, and AHR positivity was determined through immunochemistry. Survival was examined using the Kaplan-Meier method and multivariable Cox analyses.The positive expression of TDO (50.0% vs 16.7%, Pâ=â.005) and AHR (60.0% vs 8.3%, Pâ<â.001) were higher in DLBCL than in inflammatory control. The overall survival of IDO, TDO, and AHR positive expression in DLBCL patients was 34.6, 26.7, and 32.2 months, respectively, which is significantly shorter than that of the corresponding negative patients (49.0 months, Pâ=â.04; 58.2 months, Pâ<â.001; 58.0 months, Pâ<â.001; respectively). The multivariable analysis showed that TDO expression and Ann-Arbor stage were independently associated with PFS (TDO: HRâ=â8.347, 95%CI: 2.992-23.289, Pâ<â.001; stage: HRâ=â2.729, 95%CI: 1.571-4.739, Pâ<â.001) and OS (TDO: HRâ=â9.953, 95%CI: 3.228-30.686, Pâ<â.001; stage: HRâ=â2.681, 95%CI: 1.524-4.719, Pâ=â.001) in DLBCL patients.Overexpression of IDO, TDO, and AHR is associated with poor survival of patients with DLBCL and could be involved in the immune escape of cancer cells. Further studies are necessary to determine whether these proteins can be targeted by treatment regimens.
Assuntos
Antineoplásicos Imunológicos/uso terapêutico , Fatores de Transcrição Hélice-Alça-Hélice Básicos/fisiologia , Indolamina-Pirrol 2,3,-Dioxigenase/fisiologia , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/mortalidade , Receptores de Hidrocarboneto Arílico/fisiologia , Rituximab/uso terapêutico , Triptofano Oxigenase/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Fatores de Transcrição Hélice-Alça-Hélice Básicos/biossíntese , Feminino , Humanos , Indolamina-Pirrol 2,3,-Dioxigenase/biossíntese , Masculino , Pessoa de Meia-Idade , Prognóstico , Receptores de Hidrocarboneto Arílico/biossíntese , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento , Triptofano Oxigenase/biossíntese , Adulto JovemRESUMO
Gliomas are the most common and aggressive type of primary adult brain tumors. Although GGNBP2 has previously been considered to be a tumor suppressor gene, little is known about the association between GGNBP2 and glioma. In this study, we clearly demonstrated that GGNBP2 was downexpressed in glioma tissues, and its downexpression is related to the pathological grade and overall survival of patients with gliomas. Overexpression of GGNBP2 suppressed the proliferation, migration, and invasion of glioma cells. Mechanistically, we demonstrated that the PI3K/Akt and Wnt/ß-catenin signaling pathways were suppressed by GGNBP2 overexpression. In contrast, knockdown of GGNBP2 has precisely the opposite effect. Collectively, these data indicate that GGNBP2 shows tumor suppressive activity in human glioma cells and may stand out as a potential therapeutic target for glioma.
Assuntos
Glioma/genética , Proteínas Supressoras de Tumor/genética , Proteínas Adaptadoras de Transdução de Sinal , Linhagem Celular Tumoral , Movimento Celular/genética , Proliferação de Células , Expressão Gênica , Glioma/patologia , Humanos , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Via de Sinalização WntRESUMO
OBJECTIVE: To study the effect of low-dose erythromycin combined with sinus displacement therapy on treating sinusitis in patients with nasopharyngeal carcinoma after radiotherapy. METHOD: The sinus displacement were used with mixed liquid of metronidazole, protease and dexamethasone, and meantime roxithromycin was orally administered. RESULT: Effective rate was 97.1% in 35 nasopharyngeal carcinoma patients with sinusitis after radiotherapy. CONCLUSION: Low-dose erythromycin combined with sinus displacement therapy is effective to treat sinusitis in patients with nasopharyngeal carcinoma after radiotherapy. Its advantages are safe, effective, and easy to do.
Assuntos
Eritromicina/administração & dosagem , Neoplasias Nasofaríngeas/complicações , Sinusite/terapia , Adulto , Idoso , Carcinoma , Terapia Combinada , Eritromicina/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Carcinoma Nasofaríngeo , Neoplasias Nasofaríngeas/radioterapia , Sinusite/complicaçõesRESUMO
Reactions of a tungsten trisulfido complex of hydridotris(3,5-dimethylpyrazol-1-yl)borate (Tp*) [Et4N][Tp*WS3] (1) with 3 equiv of CuCl in CHCl3 afforded a tetranuclear anionic cluster [Et4N][Tp*W(mu3-S)3(CuCl)3] (2), while that of 1 with 3 equiv of CuNCS in MeCN produced a decanuclear neutral cluster (major product) [Tp*W(mu3-S)3Cu3(mu-NCS)3(CuMeCN)]2 (3) along with a binuclear anionic cluster (minor product) [Et4N][Tp*WO(mu-S)2(CuNCS)] (4). Solvothermal reactions of 1 with 3 equiv of CuCN in MeCN at 80 degrees C for 48 h followed by slowly cooling it to ambient temperature gave rise to a polymeric cluster [Tp*W(mu3-S)(mu-S)2Cu2(MeCN)(mu-CN)]n (5). Compounds 2-5 were characterized by elemental analysis, IR, UV-vis, 1H NMR, and single-crystal X-ray crystallography. The cluster anion of 2 has a [Tp*WS3Cu3] incomplete cube with one Cl atom coordinated at each Cu center. 3 is composed of an unprecedented centrosymmetric W2Cu8 cluster core in which each void of the two single incomplete cubane-like [Tp*W(mu3-S)3Cu3(mu-NCS)]+ cations is partially filled with an extra [Cu(MeCN)(mu-NCS)2]- anion via a pair of Cu-mu-NCS-Cu bridges. The cluster anion of 4 contains one WS2Cu core that is formed by an oxidized [Tp*WO(mu-S)2] species and one CuNCS fragment. 5 consists of butterfly shaped [Tp*W(mu3-S)(mu-S)2Cu2(MeCN)] fragments that are interconnected via cyanide bridges to form a 1D spiral chain extending along the c axis. The successful synthesis of 2-5 from 1 suggests that 1 may be an excellent synthon to the W/Cu/S clusters. In addition, the third-order nonlinear optical (NLO) properties of 1-3 in solution were also investigated by femtosecond degenerate four-wave mixing (DFWM) technique with a 80 fs pulse width at 800 nm. Although 2 was not detected to have NLO effects, 1 and 3 exhibited relatively good optical nonlinearities with the nonlinear refractive index n2 and the third-order nonlinear optical susceptibility chi(3) values being 0.79 x 10(-13) and 0.38 x 10(-14) esu (1) and 2.08 x 10(-13) and 1.00 x 10(-14) esu (3), respectively. The second-order hyperpolarizability gamma value for 3 (5.46 x 10(-32) esu) is ca. 5 times larger than that of its precursor 1.